Autolus Therapeutics plc ADR (NASDAQ: AUTL) Stock In Prove Me State
Autolus Therapeutics plc ADR (AUTL) concluded trading on Thursday at a closing price of $1.35, with 5.46 million shares of worth about $7.37 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.58% during that period and on May 08, 2025 the price saw […]
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Stock In Prove Me State
Autolus Therapeutics plc ADR (AUTL) concluded trading on Thursday at a closing price of $1.40, with 3.27 million shares of worth about $4.58 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -69.03% during that period and on April 24, 2025 the price saw […]
Autolus Therapeutics plc ADR (NASDAQ: AUTL): Reassessing Prospects
Autolus Therapeutics plc ADR (AUTL) concluded trading on Wednesday at a closing price of $7.25, with 3.77 million shares of worth about $27.33 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 163.64% during that period and on Wednesday the price saw a gain […]
Are Analysts Expecting A Better 2020 For Autolus Therapeutics plc ADR (AUTL)?
Autolus Therapeutics plc ADR (AUTL) concluded trading on Thursday at a closing price of $6.00, with 12.05 million shares of worth about $72.3 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 100.67% during that period and on Thursday the price saw a loss […]
Autolus Therapeutics plc ADR (NASDAQ: AUTL) – Not A Clear Buying Opportunity?
After grabbing 15.0 million shares, the institutional investor is now in possession of 15.0 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.62% having worth around $64.2 million. Moreover, Paradigm BioCapital Advisors LP increased its share by 5.19 million to have a control over 14.41 million shares. […]